Strategies, such as using specific DNA repair inhibitors to lower the efficacious doses of NQO1 bioactivatable drugs, would significantly reduce the risk of hemolysis and Methemoglobinemia noted with ß-lap (ARQ761). This evidence concerns the gene NQO1 and methemoglobinemia.